Condition
Relapsed Acute Myelogenous Leukemia
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results33% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Terminated2
Recruiting1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07014449Phase 1Recruiting
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
NCT01743807Phase 1Terminated
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
NCT03081780Phase 1Completed
Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML
NCT00939653Phase 2TerminatedPrimary
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Showing all 4 trials